Prolysis Ltd, a private company focused on the discovery and development of novel antibiotic therapies, and Essential Science Ltd, the technology exploitation company, today announced the establishment of a collaboration focused on the commercialisation of Prolysis’ novel bacterial cell biology expertise. The agreement will concentrate on the exploitation of Prolysis’ class-leading antibiotic screening assay technology, which the Company plans to make available on a collaborative basis to interested parties.
Essential Science will provide business development support to Prolysis aimed at establishing long-lasting relationships in the areas of library screening, in-licensing of development candidates, out-licensing of Prolysis technologies and development of new applications for Prolysis technology.